Stroke and major bleeding risk in elderly patients aged ≥ 75 years with atrial fibrillation: The loire valley atrial fibrillation project

Stroke

Volumn 46, Issue 1, 2015, Pages 143-150

  Lip, Gregory Y H ^a   Clementy, Nicolas ^b   Pericart, Lauriane ^b   Banerjee, Amitava ^a   Fauchier, Laurent ^b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY HOSPITAL OF TOURS   (France)

Author keywords

atrial fibrillation; death; stroke

Indexed keywords

ANTIVITAMIN K; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; FIBRINOLYTIC AGENT; VITAMIN K GROUP;

AGED; ANTICOAGULANT THERAPY; ARTICLE; BRAIN HEMORRHAGE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HOSPITAL PATIENT; HUMAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; RISK FACTOR; THROMBOEMBOLISM; ANTAGONISTS AND INHIBITORS; ATRIAL FIBRILLATION; BLEEDING; CHEMICALLY INDUCED; COMPLICATION; KAPLAN MEIER METHOD; STROKE; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; FEMALE; FIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; PLATELET AGGREGATION INHIBITORS; STROKE; THROMBOEMBOLISM; TREATMENT OUTCOME; VITAMIN K;

EID: 84920458154     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.114.007199     Document Type: Article

References (32)

1. Hobbs FD, Fitzmaurice DA, Mant J, Murray E, Jowett S, Bryan S, et al. A randomised controlled trial and cost-effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fbrillation in people aged 65 and over. The safe study. Health Technol Assess. 2005;9:iii-iv, ix-x, 1-74.
2. Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, et al. Worldwide epidemiology of atrial fbrillation: a Global Burden of Disease 2010 Study. Circulation. 2014;129:837-847.
3. Lubitz SA, Bauer KA, Benjamin EJ, Besdine RW, Forman DE, Gurol ME, et al. Stroke prevention in atrial fbrillation in older adults: existing knowledge gaps and areas for innovation: a summary of an American Federation for Aging Research Seminar. J Am Geriatr Soc. 2013;61:1798-1803.
4. Mant J, Hobbs FD, Fletcher K, Roalfe A, Fitzmaurice D, Lip G Y, et al; BAFTA investigators; Midland Research Practices Network (MidReC). Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fbrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet. 2007;370:493-503.
5. Rash A, Downes T, Portner R, Yeo WW, Morgan N, Channer KS. A randomised controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fbrillation (WASPO). Age Ageing. 2007;36:151-156.
6. De Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F, et al. Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease. Thromb Haemost. 2013;110:1087-1107.
7. Halperin JL, Hankey GJ, Wojdyla DM, Piccini JP, Lokhnygina Y, Patel MR, et al; ROCKET AF Steering Committee and Investigators. Effcacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fbrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Circulation. 2014;130:138-146.
8. Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fbrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011;123:2363-2372.
9. Sardar P, Chatterjee S, Chaudhari S, Lip GY. New oral anticoagulants in elderly adults: evidence from a meta-analysis of randomized trials. J Am Geriatr Soc. 2014;62:857-864.
10. Lip GY, Andreotti F, Fauchier L, Huber K, Hylek E, Knight E, et al; European Heart Rhythm Association. Bleeding risk assessment and management in atrial fbrillation patients. Executive summary of a position document from the European Heart Rhythm Association [EHRA], endorsed by the European Society of Cardiology [ESC] Working Group on Thrombosis. Thromb Haemost. 2011;106:997-1011.
11. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, et al; Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized defnitions. Circulation. 2007;115: 2344-2351.
12. Banerjee A, Taillandier S, Olesen JB, Lane DA, Lallemand B, Lip GY, et al. Ejection fraction and outcomes in patients with atrial fbrillation and heart failure: the Loire Valley atrial fbrillation project. Eur J Heart Fail. 2012;14:295-301.
13. Banerjee A, Fauchier L, Vourc'h P, Andres CR, Taillandier S, Halimi JM, Lip GY. Renal impairment and ischemic stroke risk assessment in patients with atrial fbrillation: the loire valley atrial fbrillation project. J Am Coll Cardiol. 2013;61:2079-2087.
14. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classifcation schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285: 2864-2870.
15. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refning clinical risk stratifcation for predicting stroke and thromboembolism in atrial fbrillation using a novel risk factor-based approach: the euro heart survey on atrial fbrillation. Chest. 2010;137:263-272.
16. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fbrillation: the Euro Heart Survey. Chest. 2010;138:1093-1100.
17. van Walraven C, Hart RG, Connolly S, Austin PC, Mant J, Hobbs FD, et al. Effect of age on stroke prevention therapy in patients with atrial fbril-lation: the atrial fbrillation investigators. Stroke. 2009;40:1410-1416.
18. Olesen JB, Lip GY, Lindhardsen J, Lane DA, Ahlehoff O, Hansen ML, et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fbrillation: a net clinical beneft analysis using a 'real world' nationwide cohort study. Thromb Haemost. 2011;106:739-749.
19. Banerjee A, Lane DA, Torp-Pedersen C, Lip G Y. Net clinical beneft of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fbrillation population: a modelling analysis based on a nationwide cohort study. Thromb Haemost. 2012;107:584-589.
20. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fbrillation. Ann Intern Med. 2007;146:857-867.
21. Wan Y, Heneghan C, Perera R, Roberts N, Hollowell J, Glasziou P, et al. Anticoagulation control and prediction of adverse events in patients with atrial fbrillation: a systematic review. Circ Cardiovasc Qual Outcomes. 2008;1:84-91.
22. Gallego P, Roldan V, Marín F, Romera M, Valdés M, Vicente V, et al. Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fbrillation. Thromb Haemost. 2013;110:1189-1198.
23. Udompanich S, Lip GY, Apostolakis S, Lane DA. Atrial fbrillation as a risk factor for cognitive impairment: a semi-systematic review. QJM. 2013;106:795-802.
24. Donzé J, Clair C, Hug B, Rodondi N, Waeber G, Cornuz J, et al. Risk of falls and major bleeds in patients on oral anticoagulation therapy. Am J Med. 2012;125:773-778.
25. Banerjee A, Clementy N, Haguenoer K, Fauchier L, Lip GY. Prior history of falls and risk of outcomes in atrial fbrillation: the Loire Valley atrial fbrillation project. Am J Med. 2014;127:972-978.
26. Larsen TB, Rasmussen LH, Skjøth F, Due KM, Callréus T, Rosenzweig M, et al. Effcacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fbrillation: a prospective nationwide cohort study. J Am Coll Cardiol. 2013;61:2264-2273.
27. Melgaard L, Rasmussen LH, Skjøth F, Lip GY, Larsen TB. Age dependence of risk factors for stroke and death in young patients with atrial fbrillation: a nationwide study. Stroke. 2014;45:1331-1337.
28. Olesen JB, Lip GY, Kamper AL, Hommel K, Køber L, Lane DA, et al. Stroke and bleeding in atrial fbrillation with chronic kidney disease. N Engl J Med. 2012;367:625-635.
29. Roldán V, Marín F, Fernández H, Manzano-Fernández S, Gallego P, Valdés M, et al. Renal impairment in a "real-life" cohort of anticoagu-lated patients with atrial fbrillation (implications for thromboembolism and bleeding). Am J Cardiol. 2013;111:1159-1164.
30. Olive F, Gomez F, Schott AM, Remontet L, Bossard N, Mitton N, et al. Critical analysis of French DRG based information system (PMSI) databases for the epidemiology of cancer: a longitudinal approach becomes possible. Rev Epidemiol Sante Publique. 2011;59:53-58.
31. Friberg J, Buch P, Scharling H, Gadsbphioll N, Jensen GB. Rising rates of hospital admissions for atrial fbrillation. Epidemiology. 2003;14:666-672.
32. Signorello LB, McLaughlin JK, Lipworth L, Friis S, Sørensen HT, Blot WJ. Confounding by indication in epidemiologic studies of commonly used analgesics. Am J Ther. 2002;9:199-205.